Hologic, Inc. (NASDAQ:HOLX) – Analysts at Leerink Swann dropped their Q1 2018 earnings per share estimates for shares of Hologic in a research note issued to investors on Thursday. Leerink Swann analyst R. Newitter now anticipates that the medical equipment provider will earn $0.49 per share for the quarter, down from their prior estimate of $0.52. Leerink Swann also issued estimates for Hologic’s Q2 2018 earnings at $0.51 EPS, FY2018 earnings at $2.13 EPS, FY2019 earnings at $2.37 EPS and FY2020 earnings at $2.62 EPS.
Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 EPS for the quarter, beating the consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The business had revenue of $802.90 million for the quarter, compared to the consensus estimate of $792.54 million. During the same period last year, the business posted $0.52 EPS. The company’s revenue was up 10.5% compared to the same quarter last year. ILLEGAL ACTIVITY WARNING: “Leerink Swann Research Analysts Lower Earnings Estimates for Hologic, Inc. (HOLX)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/11/12/leerink-swann-research-analysts-lower-earnings-estimates-for-hologic-inc-holx.html.
Several other analysts also recently commented on HOLX. BidaskClub downgraded Hologic from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Royal Bank Of Canada restated a “sector perform” rating and issued a $45.00 price target (down from $50.00) on shares of Hologic in a research note on Wednesday, August 9th. Barclays PLC restated an “equal weight” rating and issued a $51.00 price target (down from $53.00) on shares of Hologic in a research note on Wednesday, August 9th. Piper Jaffray Companies restated a “buy” rating and issued a $48.00 price target on shares of Hologic in a research note on Thursday. Finally, Needham & Company LLC restated a “buy” rating on shares of Hologic in a research note on Tuesday, August 1st. One analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $47.54.
Shares of Hologic (NASDAQ:HOLX) opened at $38.97 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.65 and a current ratio of 0.79. Hologic has a 52 week low of $35.76 and a 52 week high of $46.80. The company has a market capitalization of $10,723.49, a price-to-earnings ratio of 19.29, a price-to-earnings-growth ratio of 1.73 and a beta of 0.93.
A number of large investors have recently bought and sold shares of HOLX. Hall Laurie J Trustee raised its holdings in Hologic by 10.2% during the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after acquiring an additional 225 shares during the period. Commonwealth Bank of Australia raised its holdings in Hologic by 31.0% during the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after acquiring an additional 600 shares during the period. MPS Loria Financial Planners LLC bought a new stake in shares of Hologic in the second quarter worth about $191,000. National Asset Management Inc. bought a new stake in shares of Hologic in the second quarter worth about $203,000. Finally, Beck Mack & Oliver LLC bought a new stake in shares of Hologic in the second quarter worth about $209,000. 96.04% of the stock is currently owned by institutional investors and hedge funds.
In other Hologic news, Director Lawrence M. Levy sold 7,139 shares of the firm’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $39.04, for a total transaction of $278,706.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Karleen Marie Oberton sold 1,256 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $39.29, for a total value of $49,348.24. Following the sale, the vice president now directly owns 9,406 shares in the company, valued at $369,561.74. The disclosure for this sale can be found here. Over the last three months, insiders have sold 25,667 shares of company stock worth $969,299. Insiders own 0.79% of the company’s stock.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.